Key facts
- This page summarizes Rick E. Winningham's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 09 Aug 2024, 18:05.
Rick E. Winningham - 07 Aug 2024 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)
- Reporting relationship
- CHIEF EXECUTIVE OFFICER, Director
- Issuer ticker
- TBPH
- Reported as of
- 07 Aug 2024
- Net transaction value
- +$25,463
- SEC form
- 4
- Accepted by SEC
- 09 Aug 2024, 18:05:14 UTC
- Prior SEC filing
- 06 Aug 2024
- Next SEC filing
- 22 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rick E. Winningham
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Rick E. Winningham filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 09 Aug 2024.
Change
- Previous filing in this sequence was filed on 06 Aug 2024.
- Current net transaction value: +$25,463.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TBPH
transaction
Ordinary Shares
Award
- Transaction value
- $25,463
- Shares
- +3,252
- Change %
- +0.18%
- Price
- $7.83
- Shares after
- 1,839,896
- Date
- 07 Aug 2024
- Ownership
- Direct
- Footnotes
- F1
TBPH
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,900
- Date
- 07 Aug 2024
- Ownership
- As Custodian
TBPH
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 92,567
- Date
- 07 Aug 2024
- Ownership
- By Trust
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on August 7, 2024. Transaction was with the Issuer and did not involve an open market transaction.